CAESAREA, Israel, Sept. 5, 2018 /PRNewswire/ -- DarioHealth
Corp. (NASDAQ: DRIO), a leading global digital health company with
mobile health and big data solutions, announced today that
Olivier Jarry, a prominent global
life sciences and consumer health executive, has joined the Company
as President and Chief Commercial Officer. Mr. Jarry will be based
in the U.S. and will lead DarioHealth's efforts relating to global
revenue generation including B2B sales and data
monetization.
Mr. Jarry brings to DarioHealth more than 30 years of experience
improving health and living standards throughout Western and
Eastern Europe, the Americas and
Asia. He has created sustainable,
profitable growth, organically and through M&A, in the life
sciences, consumer health, and nutrition industries. Mr. Jarry has
been serving on the Company's advisory board for the last 18 months
as a business development and strategy consultant.
As Global Business Head at Bayer Diabetes Care, he managed in
excess of $1.4 billion in sales. At
Novartis he headed four regions: Europe, India, Latin
America, and Asia Pacific
in consumer health products, generics and vaccines. Mr. Jarry has
led corporate strategy and M&A at Novartis and Bayer, globally,
as well as at Bristol-Myers-Squibb, regionally. He has negotiated
M&A and alliance agreements worth up to $1.1 billion. He has also been on the executive
team and/or is a co-founder at smaller publicly traded and private
companies including Intrexon and three biotechnology companies. Mr.
Jarry serves on numerous industry, corporate, and non–profit
boards. He holds a TRIUM executive MBA from NYU Stern, LSE London,
and HEC Paris, a MEng from the French Department of Defense and a
MSc from Ecole Centrale de Paris.
Mr. Jarry was an Air Force Lieutenant and Defense Engineer with the
French military.
Olivier Jarry commented,
"Throughout my career, I have been committed to three primary goals
in healthcare: improving medical outcomes, reducing costs, and
enhancing the patient experience. In my view, DarioHealth delivers
on all three by leveraging its digital health solutions to serve
people living with chronic disease. I believe DarioHealth is
positioned to become the clear leader in digital healthcare for
diabetes. By potentially applying its technology to other chronic
conditions and growing its global sales and distribution network,
DarioHealth may emerge as a major player in the healthcare space,
while improving the lives of people around the world. I am
delighted to help the Company execute on its potential."
Erez Raphael, Chief Executive
Officer of DarioHealth stated, "We are pleased and honored that
Olivier has joined DarioHealth. He has a very impressive track
record of building global revenue through new markets at companies
including some of the largest pharmaceutical companies in the
world, as well as dynamic start-ups. Our entire global team is
eager to work with Olivier, who will manage global
commercialization, based out of our New
York office."
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital
health company serving its users with dynamic mobile health
solutions. In today's day and age, knowledge of health and
treatment is being democratized, and we believe people deserve to
know everything about their own health and have the best tools to
manage their condition. DarioHealth employs a revolutionary
approach whereby harnessing big data, we have developed a novel
method for chronic disease data management, empowering people to
analyze and personalize self-diabetes management in a totally new
way without having the disease slow them down. DarioHealth has a
commercial office in New York with
an R&D center in Caesarea,
Israel. For more information, visit
http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company describes
that it believes it is positioned to become the clear leader in
digital healthcare for diabetes and that by applying its technology
to other chronic conditions, and growing its global sales and
distribution network, it may emerge as a major player in the
healthcare space, it is using forward-looking statements. Readers
are cautioned that certain important factors may affect the
Company's actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect the Company's results
include, but are not limited to, regulatory approvals, product
demand, market acceptance, impact of competitive products and
prices, product development, commercialization or technological
difficulties, the success or failure of negotiations and trade,
legal, social and economic risks, and the risks associated with the
adequacy of existing cash resources. Additional factors that could
cause or contribute to differences between the Company's actual
results and forward-looking statements include, but are not limited
to, those risks discussed in the Company's filings with the U.S.
Securities and Exchange Commission. Readers are cautioned that
actual results (including, without limitation, the timing for and
results of the Company's commercial and regulatory plans for
Dario™) may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
DarioHealth Corporate Contact: Joao Mendes-Roter, VP Marketing,
joao@mydario.com, 1-914-775-5548
DarioHealth Investor Relations Contact: Westwicke
Partners, Dario@Westwicke.com, 1-443-213-0500
View original content with
multimedia:http://www.prnewswire.com/news-releases/dariohealth-appoints-olivier-jarry-former-head-of-diabetes-care-at-bayer-and-executive-at-novartis-and-bristol-myers-squibb-as-president-and-chief-commercial-officer-300707008.html
SOURCE DarioHealth Corp.